Diabetes care providers' manual for disaster diabetes care.

To ensure that experiences and lessons learned from the unprecedented 2011 Great East Japan Earthquake are used to improve future disaster planning, the Japan Diabetes Society (JDS) launched the "Research and Survey Committee for Establishing Disaster Diabetes Care Systems Based on Relevant Findings from the Great East Japan Earthquake" under the supervision of the Chairman of the JDS. The Committee conducted a questionnaire survey among patients with diabetes, physicians, disaster medical assistance teams (DMATs), nurses, pharmacists, and nutritionists in disaster areas about the events they saw happening, the situations they found difficult to handle, and the needs that they felt required to be met during the 2011 Great East Japan Earthquake. A total of 3,481 completed questionnaires were received. Based on these and other experiences and lessons reported following the 2011 Great East Japan Earthquake and the 2004 Niigata-Chuetsu Earthquakes, the current "Manual for Disaster Diabetes Care" has been developed by the members of the Committee and other invited authors from relevant specialties. To our knowledge, the current Manual is the world's first to focus on emergency diabetes care, with this digest English version translated from the Japanese original. It is sincerely hoped that patients with diabetes and healthcare providers around the world will find this manual helpful in promoting disaster preparedness and implementing disaster relief.

Déclaration de conflit d'intérêts

Conflict of interest statementJo Satoh received honoraria from Boehringer Ingelheim, Eli Lilly and Company, MSD, Ono pharmaceutical Co., Ltd., Sanofi, and Sumitomo Dainippon Pharma Co., Ltd. Toshinari Asakura received honoraria from Novo Nordisk. TA also received research funding from Eli Lilly Japan. Kazuhiko Hanzawa received honoraria from Daiichi Sankyo Co. Yasushi Ishigaki received honoraria from MSD Ltd., Sanofi Ltd., Bayer Yakuhin Ltd., Takeda pharmaceutical Co., Novo Nordisk Pharma Ltd., Novartis Pharma Ltd., Ono pharmaceutical company, Kowa pharmaceutical Co., Ltd. YI also received subsidies/donations from MSD Ltd., Ono pharmaceutical company. Takashi Kadowaki received honoraria from MSD Corporation, Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Kowa Pharmaceutical Co., Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., AstraZeneca K. K., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K. K., Eli Lilly Japan K. K., Nippon Boehringer Ingelheim Co. Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and Taisho Pharmaceutical Co., Ltd. TK also received research funding from MSD Corporation, Daiichi Sankyo Co., Ltd., Novo Nordisk Pharma Ltd., Sanofi K. K., and Takeda Pharmaceutical Co., Ltd. TK belongs to endowed departments by Takeda Pharmaceutical Co., Ltd., TERUMO Corporation, MSD Corporation, Novo Nordisk Pharma Ltd., and Nippon Boehringer Ingelheim Co. Ltd. Hideki Katagiri received honoraria from Astellas Pharma Inc., Daiichi-Sankyo, Taisho Toyama Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Boehringer Ingelheim, MSD K.K., and Novartis Pharma. HK also received subsidies/donations from Astellas Pharma Inc., Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Company Ltd., Sanofi K.K., Daiichi-Sankyo, Eli Lilly Japan K.K., Taisho Toyama Pharmaceutical Co., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., MSD K.K., and Novartis Pharma. Jiro Nakamura received honoraria from Astellas Pharma Inc., AstraZeneca K.K., MSD KK., Ono Pharmaceu. Co., Ltd., Daiichi Sankyo Co., Ltd., Kowa Pharmaceu, Co., Ltd., Sanofi K.K., Takeda Pharmaceu. Co., Ltd., Mitsubishi Tanabe Pharma Corp., Terumo Co., Boehringer Ingelheim Japan Co., Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., and Novo Nordisk Pharma Ltd. JN also received research funding from Kissei Pharmaceu. Co., Ltd., Boehringer Ingelheim Japan Co., Ltd., and EPS Co., Ltd. JN also received subsidies/donations from Astellas Pharma Inc., MSD K.K., Ono Pharmaceu. Co., Ltd., Sanofi K.K., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceu. Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceu. Co., Ltd., Eli Lilly Japan K.K., Japan Tobacco Inc., Novartis Pharma K.K., and Novo Nordisk Pharma Ltd. Shigeru Sakurai received subsidies/donations from Philips-Respironics Co., Ltd. Hiroaki Tomita received subsidies/donations from Kodama Hospital and Medical Corporation Association Zao-kai. Hironori Waki received subsidies/donations from Sanofi K.K. and Novo Nordisk Pharma Ltd. HW belongs to endowed departments by MSD K.K., Novo Nordisk Pharma Ltd., and Nippon Boehringer Ingelheim Co. Ltd. Koichi Yokono, Rie Ando, Masato Kasuga, Yasuhisa Kato, Koreyuki Kurosawa, Masanobu Miura, Koichi Nishitsuka, Susumu Ogawa, Tomoko Okamoto, Sadanori Sakuma, Hiroaki Satoh, Hidetoshi Shimauchi, Hiroaki Shimokawa, Wataru Shoji, Takashi Sugiyama, Akira Suwabe, Masahiro Tachi, Kazuma Takahashi, Susumu Takahashi, Yasuo Terayama, Yoko Tsuchiya, Tsuyoshi Watanabe, Kazuaki Yahata, Hidetoshi Yamashita declare that they have no conflict of interest.